ArticleHistopathology2008
Low levels of WWOX protein immunoexpression correlate with tumour grade and a less favourable outcome in patients with urinary bladder tumours.
Article in Histopathology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 38 citations in OpenAlex.
- Loss of fragile WWOX gene leads to senescence escape and genome instability.Cellular and molecular life sciences : CMLS · 2023Article
- Antineoplastic Nature ofBiology · 2023Article
- LINC01137/miR-186-5p/WWOX: a novel axis identified from WWOX-related RNA interactome in bladder cancer.Frontiers in genetics · 2023Article
- Analysis of copy number alterations in bladder cancer stem cells revealed a prognostic role of LRP1B.World journal of urology · 2022Article
- Wwox Binding to the Murine Brca1-BRCT Domain Regulates Timing of Brip1 and CtIP Phospho-Protein Interactions with This Domain at DNA Double-Strand Breaks, and Repair Pathway Choice.International journal of molecular sciences · 2022Article
- WWOX Loses the Ability to Regulate Oncogenic AP-2γ and Synergizes with Tumor Suppressor AP-2α in High-Grade Bladder Cancer.Cancers · 2021Article
- Review
- In vitro and in silico assessment of the effect of WWOX expression on invasiveness pathways associated with AP-2 transcription factors in bladder cancer.BMC urology · 2021Article
- Fragile GeneFrontiers in oncology · 2021Article
- Review
- Correlation of expression of WWOX and JNK with clinicopathologic features in human breast carcinoma.International journal of clinical and experimental pathology · 2018Article
- Functional genetic variant of WW domain-containing oxidoreductase (WWOX) gene is associated with hepatocellular carcinoma risk.PloS one · 2017Article
- WWOX: a fragile tumor suppressor.Experimental biology and medicine (Maywood, N.J.) · 2015Review
- Regulation of cell signaling and apoptosis by tumor suppressor WWOX.Experimental biology and medicine (Maywood, N.J.) · 2015Review
- Epigenetic and genetic alterations affect the WWOX gene in head and neck squamous cell carcinoma.PloS one · 2015Article
- Alternating expression levels ofOncology letters · 2014Article
- Diverse effect of WWOX overexpression in HT29 and SW480 colon cancer cell lines.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014Article
- WWOX at the crossroads of cancer, metabolic syndrome related traits and CNS pathologies.Biochimica et biophysica acta · 2014Review
- WWOX suppresses autophagy for inducing apoptosis in methotrexate-treated human squamous cell carcinoma.Cell death & disease · 2013Article
- WWOX gene and gene product: tumor suppression through specific protein interactions.Future oncology (London, England) · 2010Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 2 countries.
Funding
Abstract
aimsTo correlate the immunohistochemical detection of WWOX with histological measures and disease progression within the whole spectrum of urothelial bladder neoplasms. METHODS AND
resultsOne hundred and one patients with primary bladder tumours were retrospectively analysed. Immunohistochemically, a polyclonal antibody was utilized and the level of WWOX protein expression was analysed by using a combined score system based on intensity of the reaction and percentage of immunoreactive tumour cells. WWOX protein expression was consistently expressed in non-neoplastic urothelium, whereas a progressive loss of immunoreactivity was observed as tumour grade and stage increased (P < 0.05). Principal component analysis showed that reduced WWOX immunoexpression was significantly associated with high histological grades (P = 0.001), advanced stage (P = 0.002), tumour size (P = 0.04) and cancer progression (P = 0.028). Invasive urothelial carcinomas of the bladder with squamous metaplasia presented the lowest levels of WWOX protein. Kaplan-Meier analyses demonstrated a significant correlation between loss of WWOX expression and a shorter progression-free survival (P = 0.042), whereas the prediction of overall survival achieved borderline significance (P = 0.053).
conclusionLoss of WWOX immunoexpression strongly correlates with classical clinicopathological factors and appears to be a potential predictive marker of progressive disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.